Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

22nd Century Group Inc (XXII)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 258,011
  • Shares Outstanding, K 124,643
  • Annual Sales, $ 26,430 K
  • Annual Income, $ -7,970 K
  • 60-Month Beta 1.79
  • Price/Sales 9.53
  • Price/Cash Flow N/A
  • Price/Book 3.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/09/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2111 Cigarettes

    Tobacco

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +13.04%
on 04/23/19
2.40 -13.33%
on 05/06/19
+0.22 (+11.83%)
since 04/22/19
3-Month
1.58 +31.65%
on 03/05/19
2.56 -18.75%
on 02/25/19
-0.46 (-18.11%)
since 02/22/19
52-Week
1.58 +31.65%
on 03/05/19
3.29 -36.78%
on 10/10/18
unch (unch)
since 05/22/18

Most Recent Stories

More News
22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update

--Company's financial position remains strong; cash, cash equivalents, and short-term investment securities totaled approximately $51.9 million.

XXII : 2.08 (+0.48%)
Growing Body of Research Adds Credibility to Cannabis' Medical Claims

As the burgeoning cannabis market expands around the globe, most countries have or are moving towards adopting cannabis legislation specifically for medical use. The medical cannabis marketplace is currently...

ABT : 76.26 (+0.30%)
PHCEF : 5.7660 (-4.22%)
BBRRF : 0.4205 (-7.17%)
TLRY : 46.24 (+3.72%)
BBM.CN : 0.560 (-6.67%)
XXII : 2.08 (+0.48%)
PCLO.VN : 7.680 (-5.65%)
ABBV : 81.59 (+0.88%)
KHRNF : 2.4100 (-0.41%)
22nd Century's Pre-Market Tobacco Application for VLN(TM) Cigarettes Advances with Completed FDA Inspection

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis ...

XXII : 2.08 (+0.48%)
Grossly Misleading "Short and Distort" Article Wrongfully Attempts to Dupe 22nd Century Group Shareholders

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis ...

XXII : 2.08 (+0.48%)
22nd Century Group Hires Former Imperial Brands Head of Regulatory Science

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research,...

XXII : 2.08 (+0.48%)
IMBBF : 27.7300 (+0.03%)
Some New Patients Choose CBD in Lieu of Opioids to Treat Persistent Ailments

Nearly 20% of U.S. adults suffer from chronic pain, while 8% are diagnosed with high-impact chronic pain, according to the National Institute of Health. Researchers from the Centers for Disease Control...

MDCL : 3.1600 (+5.69%)
MRMD : 3.0850 (-1.66%)
XXII : 2.08 (+0.48%)
NLBS : 0.2250 (-4.21%)
TRST.TO : 7.94 (+0.76%)
PBIO : 3.0600 (-0.97%)
CTST : 5.90 (+0.34%)
22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research,...

XXII : 2.08 (+0.48%)
Report: Developing Opportunities within 22nd Century Group, Darling Ingredients, Silvercorp Metals, Trevena, Star Bulk Carriers, and AngioDynamics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of 22nd Century Group, Inc (NYSE:XXII),...

TRVN : 1.27 (-3.05%)
DAR : 20.13 (+0.45%)
SBLK : 8.13 (-1.45%)
XXII : 2.08 (+0.48%)
SVM : 2.08 (-4.15%)
ANGO : 19.26 (+0.94%)
Hemp and CBD Popularity Reaches New Heights With Recent Legislative Breakthroughs

Hemp was recently pushed into the spotlight after Kentucky Senator Mitch McConnell had advocated for its legalization. McConnell's support ultimately led hemp to be legalized in the recent passing of the...

NTEC : 5.13 (+4.06%)
KSHB : 4.8700 (-0.61%)
XXII : 2.08 (+0.48%)
CIIX : 0.4410 (-2.00%)
TRST.TO : 7.94 (+0.76%)
CTST : 5.90 (+0.34%)
22nd Century Group Issues Annual Letter to Shareholders

--22nd Century will substantially increase Company's investment in hemp/cannabis

XXII : 2.08 (+0.48%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Rising.

See More Share

Trade XXII with:

Business Summary

22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products...

See More

Key Turning Points

2nd Resistance Point 2.11
1st Resistance Point 2.09
Last Price 2.08
1st Support Level 2.03
2nd Support Level 1.99

See More

52-Week High 3.29
Fibonacci 61.8% 2.64
Fibonacci 50% 2.43
Fibonacci 38.2% 2.23
Last Price 2.08
52-Week Low 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar